Updated:
MEDA Ventures
MEDA Ventures is a physician-led venture firm investing in seed-stage digital health, therapeutics, and medical-device companies.
MEDA Ventures
MEDA Ventures was founded on the premise that practicing physicians and research scientists bring a distinct lens to healthcare investing. Managing Partners Elizabeth Cho-Fertikh, Tomas Philipson, and Carolyn Campbell anchor a team whose clinical and regulatory expertise shapes every mandate. The firm’s network spans institutions such as Mass General Brigham and Stanford, which it leverages for diligence and for portfolio-company business development. The firm targets seed and start-up stage healthcare companies across digital health, therapeutics, and medical devices. Its investment model emphasizes access to de-risked deal flow sourced through the partners’ clinical networks. The group has developed an insurance-like product to underwrite clinical-trial costs for its startups — a structural feature designed to buffer both the firm and its founders against trial failures. Confirmed portfolio companies include Nested Knowledge, the evidence-synthesis platform led by Kevin Kallmes, and DynamiCare Health, the digital-therapeutics company founded by Eric Gastfriend. MEDA Ventures operates from Arlington, Virginia, with a venture-partner model that extends its capabilities into health economics, FDA regulatory strategy, and large health-system adoption. The firm has not publicly disclosed its assets under management or total deployment. Venture Partners include Anupam B. Jena, host of the Freakonomics podcast and a physician at Mass General Brigham, and Eric Sun, an anesthesiologist at Stanford University. What separates MEDA Ventures from a standard early-stage healthcare fund is its clinical-trial underwriting infrastructure. The firm couples patient-capital provision with a risk-transfer mechanism that is uncommon in the seed-stage venture landscape — a structure that makes MEDA simultaneously an investor and a clinical-development partner.
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Arlington
Corporate office
Arlington, VA, United States
Principals
Elizabeth Cho-Fertikh
Managing Partner
Tomas Philipson
Managing Partner
Carolyn Campbell
Managing Partner
Sector focus
Frequently asked questions
Who makes investment decisions at MEDA Ventures?
Investment decisions are led by Managing Partners Elizabeth Cho-Fertikh (therapeutics, regulatory strategy), Tomas Philipson (health economics), and Carolyn Campbell (fund management, legal). The firm’s venture partners — practicing physicians and researchers from institutions like Mass General Brigham and Stanford — contribute to deal-specific diligence, but the Managing Partners retain decision-making authority.
What does MEDA Ventures’ clinical-trial underwriting product do?
According to MEDA’s website, the firm has developed a product that can underwrite coverage of a portfolio company’s clinical-trial costs, financially protecting both startups and investors from trial failures. The mechanics — whether a balance-sheet commitment, an insurance wrapper, or a third-party facility — have not been publicly detailed. It is positioned as a differentiated de-risking tool for early-stage healthcare companies.
How does MEDA Ventures source its deals?
The firm attributes deal flow to its partners’ standing as former healthcare customers, clinicians, and key opinion leaders. Its network of early-adopting medical centers is cited as the channel that attracts startups and co-investors. The firm states this network also supports business development and potential exits for portfolio companies.
Is MEDA Ventures a single family office or an institutional venture firm?
MEDA Ventures operates as an asset manager structured as a venture capital group, not a single-family office. Its partners are physicians and scientists rather than a single wealth-origin family. The firm has not disclosed the identity of its limited partners.
What stages does MEDA Ventures target with its investments?
MEDA Ventures focuses on early-stage healthcare companies, specifically seed and start-up phases, as described in its own materials. Its portfolio companies include Nested Knowledge and DynamiCare Health, both of which were at early commercial or clinical-validation stages when the relationship was disclosed.
How can startups submit a pitch to MEDA Ventures?
MEDA Ventures does not publish an open submission process or portal. Contact is routed through its general email address, info@meda.vc, per the firm’s website. Given its network-driven sourcing model, warm introductions through its clinical and scientific network are likely the primary path for consideration.
Does MEDA Ventures disclose its assets under management?
No. MEDA Ventures has not publicly disclosed an AUM or total deployment figure. The firm does not appear in the standard AUM-tracking databases. The absence of public disclosure is consistent with an early-stage or tightly held vehicle.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: